Rob Dawber

Rob joined the group in August 2022 as a Postdoctoral Research Associate, where he investigates lysine demethylases (KDMs) in relation to the chemistry of epigenetics and associated cancers. He received his MChem degree at the University of Leeds in 2018. As part of his studies, he spent a year in the pharmaceutical industry working for YProTech (now Apex Molecular) where he developed a catalogue of compounds for use in antibody drug conjugate (ADC) research. Following his industrial placement, Rob returned to Leeds to complete his research project in the Fishwick group, where he employed structure-based drug design to develop membrane-bound ion channel inhibitors with antimalarial potential. In July 2022, Rob completed his PhD at the same institute through the MRC DiMeN DTP programme, where he developed peptidomimetic inhibitors of key protein-protein interactions of the Aurora A kinase under the supervision of Prof. Richard Bayliss and Prof. Andy Wilson.